---
title: "KRM Ayurveda (760624) — Share Price, Financials & Analysis"
symbol: "760624"
company: "KRM Ayurveda"
canonical: "https://tapetide.com/stocks/760624"
isin: "INE1MTV01019"
nse_symbol: "KRMAYURVED"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 629.32
generated_at: "2026-09-13T18:37:37.038Z"
---

# KRM Ayurveda (760624)

Canonical page: https://tapetide.com/stocks/760624

## Company

- **NSE Symbol:** KRMAYURVED
- **ISIN:** INE1MTV01019
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Stock Type:** EQUITY
- **Listed Since:** 2026-01-29
- **F&O Eligible:** No

## Latest Price

- **Price:** ₹307.7
- **Change:** +13.85 (+4.71%)
- **Open:** ₹292
- **Day High:** ₹310.5
- **Day Low:** ₹291.6
- **Previous Close:** ₹293.85
- **Volume:** 311000
- **As Of:** 2026-09-11T09:59:58+00:00

## Key Fundamentals

Observed at 2026-09-11T04:35:05.239225Z.

- **Market Cap:** ₹629.32 Cr
- **Classification:** SME
- **P/E (reported):** 0
- **Book Value:** ₹56.55
- **Price to Book:** 5.2
- **Dividend Yield:** 0%
- **ROE:** 50.67%
- **ROCE:** 42.75%
- **Debt to Equity:** 1.28
- **Revenue (yearly):** ₹101.69 Cr
- **Net Income:** ₹19.86 Cr
- **EBITDA:** ₹30.5 Cr
- **52-Week High:** ₹343.95
- **52-Week Low:** ₹156.15
- **RSI (14):** 56.33

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 96.63% | -100.85% | -104.11% |
| ebitda margin growth | 12.5% | 17.59% | 159.9% | — |
| net income growth | 16.67% | 64.13% | 484.12% | — |
| revenue growth | 1.54% | 32.24% | 14.58% | — |
| roce | — | 107.73% | 7.09% | — |
| roe | — | 74.91% | 56.82% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2025 |
| --- | --- |
| Sales | 48 |
| Expenses | 36 |
| Operating Profit | 13 |
| OPM % | 27 |
| Other Income | 0 |
| Interest | 2 |
| Depreciation | 1 |
| Profit before tax | 11 |
| Tax % | 26 |
| Net Profit | 8 |
| EPS in Rs | 5.24 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- |
| Sales | 89 | 67 | 77 |
| Expenses | 78 | 60 | 57 |
| Operating Profit | 11 | 8 | 19 |
| OPM % | 13 | 11 | 25 |
| Other Income | 0 | 0 | 0 |
| Interest | 1 | 2 | 2 |
| Depreciation | 1 | 1 | 1 |
| Profit before tax | 10 | 5 | 16 |
| Tax % | 25 | 28 | 26 |
| Net Profit | 8 | 3 | 12 |
| EPS in Rs | 5066.67 | 2273.33 | 806.67 |
| Dividend Payout % | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
| --- | --- | --- | --- | --- |
| Equity Capital | 0.15 | 0.15 | 0.15 | 16 |
| Reserves | 8 | 12 | 24 | 21 |
| Borrowings | 20 | 23 | 31 | 25 |
| Other Liabilities | 11 | 9 | 12 | 17 |
| Total Liabilities | 39 | 44 | 67 | 78 |
| Fixed Assets | 23 | 23 | 27 | 27 |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| Other Assets | 16 | 21 | 40 | 52 |
| Total Assets | 39 | 44 | 67 | 78 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- |
| Cash from Operating Activity | 4 | -1 | 0 |
| Cash from Investing Activity | -23 | 0 | -4 |
| Cash from Financing Activity | 19 | 1 | 6 |
| Net Cash Flow | 0 | 0 | 2 |

### Ratios

| Item | Mar 2023 | Mar 2024 | Mar 2025 |
| --- | --- | --- | --- |
| Debtor Days | 32 | 30 | 58 |
| Inventory Days | 13 | 53 | 296 |
| Days Payable | 100 | 141 | 205 |
| Cash Conversion Cycle | -55 | -58 | 149 |
| Working Capital Days | 9 | 48 | 64 |
| ROCE % | — | 22 | 42 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2025 | Mar 2026 |
| --- | --- | --- |
| Promoters | 92.16% | 69.15% |
| FIIs | 0% | 3.86% |
| DIIs | 0% | 3.34% |
| Government | 0% | 0% |
| Public | 0% | 14.87% |
| Others | 7.84% | 8.78% |
| No. of Shareholders | 54 | 536 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 11 / 6 / 2

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 290.61 | Buy |
| EMA (10) | 291.11 | Buy |
| SMA (20) | 284.37 | Buy |
| EMA (20) | 287.22 | Buy |
| SMA (50) | 274.62 | Buy |
| EMA (50) | 276.41 | Buy |
| SMA (100) | 260 | Buy |
| EMA (100) | 257.74 | Buy |
| SMA (200) | — | Neutral |
| EMA (200) | — | Neutral |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 62.41 | Neutral |
| MACD (12,26,9) | 5.02 | Buy |
| Stochastic (14,3,3) | 66.56 | Neutral |
| ADX (14) | 28.63 | Buy |
| Williams %R (14) | -6.79 | Sell |
| ATR (14) | 13.31 | High Volatility |
| ROC (12) | 9.97 | Buy |
| Stoch RSI (14) | 100 | Sell |
| UO (7,14,28) | 53.07 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 July 2026 - KRM Ayurveda plans a new Gurugram hospital adding 60-100 beds, starting August 2026, funded by own funds. | [Updates 9 July 2026 - KRM Ayurveda plans a new Gurugram hospital adding 60-100 beds, starting August 2026, funded by own funds.](https://nsearchives.nseindia.com/corporate/KRMIPO_09072026143929_STX_letter_Gurugram_Proposal_09072026.pdf) |
| 6 May 2026 - Audio recording shared for earnings call on audited standalone results for H2 and FY ended March 31, 2026. | [Analysts/Institutional Investor Meet/Con. Call Updates 6 May 2026 - Audio recording shared for earnings call on audited standalone results for H2 and FY ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/KRMIPO_06052026115828_Audio_Recording_Earnings_Con_Call_06052026.pdf) |
| 6 April 2026 - KRM Ayurveda opened a new 2,760.90 sq. ft. day care center in Janakpuri, New Delhi, on a 9-year lease from April 10, 2026. | [Updates 6 April 2026 - KRM Ayurveda opened a new 2,760.90 sq. ft. day care center in Janakpuri, New Delhi, on a 9-year lease from April 10, 2026.](https://nsearchives.nseindia.com/corporate/KRMIPO_06042026171051_Janakpuri_06042026__1_.pdf) |
| 4 May 2026 - Investor presentation for H2/FY2025-26 financial performance; conference call scheduled May 5, 2026. | [Investor Presentation 4 May 2026 - Investor presentation for H2/FY2025-26 financial performance; conference call scheduled May 5, 2026.](https://nsearchives.nseindia.com/corporate/KRMIPO_04052026182407_Investor_Presentation_04052026.pdf) |
| 4 May 2026 - Addendum submitted with omitted audit report for FY2026 audited results. | [Updates 4 May 2026 - Addendum submitted with omitted audit report for FY2026 audited results.](https://nsearchives.nseindia.com/corporate/KRMIPO_04052026205607_Addendum_Financial_Result_04052026.pdf) |
| 30 June 2026 - Trading window closed from 1 July 2026 until 48 hours after Q1 results. | [Trading Window 30 June 2026 - Trading window closed from 1 July 2026 until 48 hours after Q1 results.](https://nsearchives.nseindia.com/corporate/KRMIPO_30062026111613_Trading_window_closure_30062026.pdf) |
| 29 June 2026 - SDD compliance certificate issued for FY ended March 31, 2026. | [Structural Digital Database 29 June 2026 - SDD compliance certificate issued for FY ended March 31, 2026.](https://nsearchives.nseindia.com/corporate/KRMIPO_29062026175803_STX_Letter_SDD_29062026.pdf) |
| 29 April 2026 - KRM Ayurveda schedules earnings call on May 5, 2026 at 4:00 PM for H2 FY26 and FY26 audited results. | [Analysts/Institutional Investor Meet/Con. Call Updates 29 April 2026 - KRM Ayurveda schedules earnings call on May 5, 2026 at 4:00 PM for H2 FY26 and FY26 audited results.](https://nsearchives.nseindia.com/corporate/KRMIPO_29042026175051_Intimation_Earnings_Confrence_Call_05052026.pdf) |
| 28 March 2026 - KRM Ayurveda: trading window closed from 01-Apr-2026 until 48 hours after audited FY2026 results; board meeting date TBA. | [Trading Window 28 March 2026 - KRM Ayurveda: trading window closed from 01-Apr-2026 until 48 hours after audited FY2026 results; board meeting date TBA.](https://nsearchives.nseindia.com/corporate/KRMIPO_28032026132132_Tradingwindowclosure_01042026-01062026__1_.pdf) |
| 28 March 2026 - Board approved internal and secretarial auditor appointments; authorized renting property from related parties. | [Outcome of Board Meeting 28 March 2026 - Board approved internal and secretarial auditor appointments; authorized renting property from related parties.](https://nsearchives.nseindia.com/corporate/KRMIPO_28032026165244_BM_Outcome_28032026__1_.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:37:37.038Z.